Common Contracts

EX-10.4 11 a2232278zex-10_4.htm EX-10.4 CONFIDENTIAL COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MERCK KGaA

Collaboration and Commercial License Agreement • May 5th, 2020 • England and Wales

• Contract Type
  Collaboration and Commercial License Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  England and Wales

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

CONFIDENTIAL COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MERCK KGaA

Collaboration and Commercial License Agreement • June 1st, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • England and Wales

• Contract Type
  Collaboration and Commercial License Agreement
• Filed
  June 1st, 2017
• Company
  Mersana Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  England and Wales

This Collaboration and Commercial License Agreement, effective as of June 23, 2014 (“Effective Date”), is by and between Mersana Therapeutics, Inc., a Delaware corporation, having its principal place of business at 840 Memorial Drive Cambridge, MA 02139 (“Mersana”) and Merck KGaA, a corporation with general partners having its principal place of business at Frankfurter Str. 250, 64293 Darmstadt, Germany (“Merck”). Mersana and Merck may be referred to in this Agreement individually as a “Party” or collectively as the “Parties”.

CONFIDENTIAL COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MERCK KGaA

Collaboration and Commercial License Agreement • March 17th, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • England and Wales

• Contract Type
  Collaboration and Commercial License Agreement
• Filed
  March 17th, 2017
• Company
  Mersana Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  England and Wales

This Collaboration and Commercial License Agreement, effective as of June 23, 2014 (“Effective Date”), is by and between Mersana Therapeutics, Inc., a Delaware corporation, having its principal place of business at 840 Memorial Drive Cambridge, MA 02139 (“Mersana”) and Merck KGaA, a corporation with general partners having its principal place of business at Frankfurter Str. 250, 64293 Darmstadt, Germany (“Merck”). Mersana and Merck may be referred to in this Agreement individually as a “Party” or collectively as the “Parties”.